Table 1.

Results from trials: Interferon-ribavirin combined treatments in patients with end-stage renal disease and hepatitis C virus ınfection

Ref.	Year	No. of patients	Proportion with HCV genotype 1 (%)	Treatment	SVR (%)	Dropout (%)
Tan et al[85]	2001	5	NA	IFN-3.0 MU/d to 3 times/wk + RBV 200 mg/d, 3 times/wk for 40 wk	NA	40
Mousa et al[86]	2004	20	60-66	IFN-3.0 MU/d to 3 times/wk + RBV 200 mg/d, 3 times/wk
				For 24 wk	66	0
				For 48 wk	55	0
Bruchfeld et al[87]	2006	6	66	PegIFN - 50 μg/wk + RBV 200-400 mg/d for 24-48 wk (depending on genotype)	50	50
Rendina et al[88]	2007	35	45.7	PegIFN-α2a 135 μg/wk + RBV 200 mg/d for 24-48 wk (depending on genotype)	97	15

IFN: İnterferon; NA: Not available; PegIFN: Pegylated IFN; RBV: Ribavirin; SVR: Sustained virological response; HCV: Hepatitis C virus.